Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20335022 | 1.00 | MEN1 (0.48) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL6168152 | 0.87 | — | — | |
| SCHEMBL30530860 | 0.87 | — | — | |
| SCHEMBL6515271 | 0.86 | MEN1 (0.50) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL536304 | 0.83 | MEN1 (0.48) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL7418029 | 0.83 | — | — | |
| SCHEMBL30832481 | 0.83 | MEN1 (0.50) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL10476849 | 0.83 | PREP (0.61) | KMT2ANPSR1 | |
| SCHEMBL317040 | 0.82 | MEN1 (0.47) | MEN1KMT2ANPSR1 | |
| SCHEMBL839569 | 0.82 | MEN1 (0.47) | MEN1KMT2ANPSR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345179-B2 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20070105935-A1 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1623975-A1 | PROCESS FOR PRODUCING PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-08 | — | — | EP | disclosed |
| US-5646126-A | ANTITUMOR AGENTS EFFECTIVE AGAINST MULTIPLE DRUG RESISTANT CELL LINES | EPOCH PHARMACEUTICALS | 1997-07-08 | — | — | US | disclosed |
| EP-0748331-A1 | MODIFIED OLIGONUCLEOTIDE DUPLEXES HAVING ANTICANCER ACTIVITY | EPOCH PHARMACEUTICALS, INC. (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995023162-A1 | MODIFIED OLIGONUCLEOTIDE DUPLEXES HAVING ANTICANCER ACTIVITY | MICROPROBE CORPORATION (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105935-A1 | Process for producing pyrrolidine derivative | ACSL4, ALDH18A1, LTA | MEN1 2854/4885KMT2A 1387/4885NPSR1 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.